leadf
logo-loader
view4D pharma plc

4D Pharma bullish on progress of microbiome-based cancer research

4D's lead oncology product has demonstrated immune-stimulatory characteristics in pre-clinical models

doctor and patient
Microbiome-based treatment is what 4D is investigating

4D Pharma PLC (LON:DDDD) will present data today outlining how its microbiome-based cancer treatment might activate the body’s response to the disease.

The company’s lead oncology candidate is MRx0518, a strain of live bacteria extracted from human faecal samples that in pre-clinical models has shown it can stimulate the immune system.

Duncan Peyton, chief executive, will highlight aspects of the mode of action of MRx0518 at the Microbiome R&D and Business Collaboration Forum in Rotterdam. 

Specific component

4D has identified a specific component of the bacteria, flaA, that plays a key role in the activity of MRx0518 and the body's response to cancer. 

Peyton said: "This is a key step in the development of a true microbiome-derived pharmaceutical product for the treatment of cancer. 

"Understanding the mode of action of MRx0518, through the identification of a specific gene product and its interaction with a high profile human oncology target, gives greater insight into its potential applications and benefits to cancer patients.”

Plans are at an advanced stage to open clinical studies for MRx0518 in the UK and the US in the near future.

Quick facts: 4D pharma plc

Price: 99 GBX

LSE:DDDD
Market: LSE
Market Cap: £130.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

4D Pharma shares could re-test 2016’s £10 highs if they do this one thing

The 4D Pharma (LON:DDDD) share price could go on to re-test last year’s highs of £10 if they can break above the 200-day moving average, claims Zak Mir. “Really, one would want to see the shares break outside that range in order to determine fresh direction,” Mir explains in the Proactive...

on 13/1/17

2 min read